NCT06916416

Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: University of Cologne · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.

Conditions

• Classical Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy

Timeline

• Start date: 2025-06-01
• Primary completion: 2026-06-01
• Completion: 2028-06-01
• First posted: 2025-04-08
• Last updated: 2025-04-08